picoplatin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals for the treatment of patients with solid tumors.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

amd473 | amd 473 | amd-473 | amminedichloro(2-methylpyridine)platinum(ii) | cis-amminedichloro(2-methylpyridine)platinum(ii) | jm473 | jm-473 | nx-473 | picoplatin | (sp-4-3)-amminedichloro(2-methylpyridine)platinium | zd0473 | zd 0473 | zd-0473

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Breast Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1/Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Head and Neck Neoplasms (Phase 1)

Intestinal Neoplasms (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue